Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
  1. Home
  2. Publications
  3. Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC

Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC

Authors:
  • JGJovylyn G. Gasendo
    Jovylyn G. Gasendo
  • SCStacia Chan
    Stacia Chan
  • HPHetika V. Patel
    Hetika V. Patel
  • ASAlison E. Smith
    Alison E. Smith
  • LKLinda Kessler
    Linda Kessler
  • YLYahu A. Liu
    Yahu A. Liu
  • AMAmitava Mitra
    Amitava Mitra
  • FBFrancis Burrows
    Francis Burrows
  • SMShivani Malik
    Shivani Malik

Open Access
Publisher website
Google Scholar
  • 2 September 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.33414216
Abstract
KO-2806 is tolerable in combination with anti-VEGFR TKIs in RCC tumors progressing on TKIs.
Keywords
  • ANGIOGENESIS
  • ENDOTHELIAL CELL FUNCTIONS
  • DRUG RESISTANCE
  • GENITOURINARY CANCERS
  • RENAL CANCER
  • PRECLINICAL MODELS
  • XENOGRAFT MODELS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.